111 Capital Sells 1,403 Shares of Eli Lilly and Company $LLY

Key Points

• 111 Capital decreased its ownership in Eli Lilly and Company by 48.0%, selling 1,403 shares and holding 1,518 shares valued at $1,183,000 as of the latest SEC filing.
• Eli Lilly reported $15.56 billion in revenue for the recent quarter, exceeding analyst estimates of $14.40 billion, and achieved a 37.6% year-over-year revenue growth.
• Several analysts have adjusted their price targets for Eli Lilly, with Deutsche Bank lowering its target from $1,010.00 to $900.00, while maintaining a "buy" rating on the stock.

111 Capital trimmed its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 48.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,518 shares of the company's stock after selling 1,403 shares during the quarter. 111 Capital's holdings in Eli Lilly and Company were worth $1,183,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Matrix Trust Co raised its stake in Eli Lilly and Company by 25.9% in the 1st quarter. Matrix Trust Co now owns 267 shares of the company's stock valued at $221,000 after acquiring an additional 55 shares during the period. Beacon Financial Group raised its position in shares of Eli Lilly and Company by 4.2% in the first quarter. Beacon Financial Group now owns 446 shares of the company's stock valued at $368,000 after purchasing an additional 18 shares during the period. Finally, Charles Schwab Trust Co raised its position in shares of Eli Lilly and Company by 41.1% in the first quarter. Charles Schwab Trust Co now owns 453 shares of the company's stock valued at $374,000 after purchasing an additional 132 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 2.5%

Shares of LLY opened at $840.46 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The firm's 50 day moving average is $734.60 and its 200-day moving average is $766.47. The stock has a market capitalization of $795.47 billion, a PE ratio of 54.93, a P/E/G ratio of 1.14 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the company earned $3.92 EPS. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling

In other news, Director Gabrielle Sulzberger bought 117 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on LLY shares. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target on the stock. in a report on Sunday, August 17th. Morgan Stanley lowered their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research note on Friday. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and increased their target price for the stock from $675.00 to $700.00 in a research note on Wednesday, August 27th. Finally, Berenberg Bank reiterated a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $933.39.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.